0.00Open0.00Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover1178.74%IV-7.86%PremiumJul 19, 2024Expiry Date1.64Intrinsic Value100Multiplier-4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9535Delta0.0447Gamma--Leverage Ratio-2.6916Theta0.0000Rho0.00Eff Leverage0.0002Vega
Cullinan Therapeutics Stock Discussion
NEWS
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
• $Cullinan Therapeutics(CGEM.US)$ +22.4% (Cullinan Management and Taiho Pharmaceutical to collaborate to jointly develop and commercialize CLN081/TAS6417 and Taiho's acquisition of Cullinan Pearl)
• $Lordstown Motors(RIDE.US)$ +17.2% (closes asset purchase agreement with Foxconn)
• $Applovin(APP.US)$ +15.5%(In reaction to earnings)
• $SmartRent(SMRT.US)$ +15.4%(In reaction to earnings)
• $Coupang(CPNG.US)$ +14.3%(In reaction to earn...
No comment yet